Compare IHD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IHD | NYXH |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | Belgium |
| Employees | N/A | 154 |
| Industry | Investment Managers | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.5M | 134.5M |
| IPO Year | N/A | 2021 |
| Metric | IHD | NYXH |
|---|---|---|
| Price | $7.18 | $3.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | ★ 91.9K | 22.7K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | ★ 10.32% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $213.98 |
| Revenue Next Year | N/A | $126.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.46 | $2.76 |
| 52 Week High | $7.59 | $8.64 |
| Indicator | IHD | NYXH |
|---|---|---|
| Relative Strength Index (RSI) | 49.89 | 47.42 |
| Support Level | $7.09 | $2.80 |
| Resistance Level | $7.19 | $3.37 |
| Average True Range (ATR) | 0.12 | 0.14 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 10.87 | 39.80 |
Voya Emerging Markets High Dividend Equity Fund is a diversified closed-end management investment company. Its primary investment objective is to provide total return through a combination of current income, capital gains, and capital appreciation. The company seeks to achieve its investment objectives by investing principally in a portfolio of equity securities, and issuers in emerging market countries. The Fund will also normally seek to secure gains and enhance the stability of returns over a market cycle by writing (selling) call options on selected exchange-traded funds (ETFs) and/or international, regional, or country indices of equity securities, and/or on equity securities.
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.